ChonDRAgon :A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX[1]109 in Unresectable or Metastatic Conventional Chondrosarcoma
DeFI Study: A randomized, double-blind, placebo-controlled, phase III trial of Nirogacestat versus placebo in adult patients with progressing desmoid tumours/aggressive fibromatosis
E7389-G000-213 (BOLD): A phase I/II single-arm study evaluating the safety and efficacy of Eribulin Mesilate in combination with Irinotecan in children with refractory or recurrent solid tumours
E7080-G000-230 (OLIE): A multicenter, open-label, randomized phase II study to compare the efficacy and safety of Lenvatinib in combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in children, adolescents and young adults with relapsed or refractory Osteosarcoma
HGUS EORTC 62113: A randomised double-blind phase II study evaluating the role of maintenance Cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) or response to Doxorubicin +/-Ifosfamide or in metastatic first line treatment
J1S-MC-JV01: Protocol Addendum J1S-MC-JV01(a) A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
IMRIS: A phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma
INTRIGUE: A phase III, interventional, randomised, multicentre, open-label study of DCC-2618 vs sunitinib in patients with advanced gastrointestinal stromal tumours after treatment with imatinib
Kindred Study: The international sarcoma kindred study: a global multi-site prospective cancer genetics study
KCP-330-020 (SEAL): A phase II/III multicentre, randomised, double-blind study of Selinexor (KPT - 330) verus placebo in patient with advanced unresectable differentiated liposarcoma
RAPPER: Radiogenomics: Assessment of polymorphisms for predicting the effects of radiotherapy
REDUCE (EORTC 1762): Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumour of bone: a multicentre phase II study
MOTION: A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)
